病毒性肺炎小儿雾化吸入重组人干扰素α1b的安全性及疗效研究

Viral pneumonia pediatric atomization inhalation of restructuring the efficacy and safety of interferon α1 b research

目的探讨雾化吸入重组人干扰素α1b对治疗小儿病毒性肺炎的安全性和疗效。方法选取病毒性肺炎患儿105例为研究对象,随机分为观察组和对照A组、B组,各35例。对照组给予肌肉注射重组人干扰素α1b的治疗方案,而观察组给予雾化吸入重组人干扰素α1b,观测用药后的临床症状、对比不良反应事件。结果观察组的显著有效率为62.86%,较对照组的34.29%、31.34%有明显差异(P<0.05)。观察组总的有效率为97.14%,对照组则分别为74.29%、77.14%,同样这两组对比观察组更低,差异有统计学意义(P<0.05)。观察组的咳嗽、气喘、肺部啰音3项症状评分明显低于两组对照组,差异有统计学意义(P<0.05)。在不良反应发生率中,观察组患儿发生头痛、肌肉乏力酸痛、呼吸道局部不适、发热的情况为14.29%,与两组对照组的14.29%,17.14%,差异无统计学意义。结论雾化吸入重组人干扰素α1b治疗小儿病毒性肺炎临床疗效显著,不良反应较低,值得临床进一步推广和应用。

Objective To investigate the atomization inhalation human recombinant interferon α1b on the safety and efficacy for the treatment of infantile viral pneumonia. Methods Choose 105 cases of children viral pneumonia as the research object, and randomly divided into control group and observation group, 35 cases. The control group given intramuscular human recombinant interferon α1b treatment, the observation group was given atomization inhalation human recombinant interferon α1b, observation of clinical symptoms, the medicine adverse events. Results Observation group markedly effective rate was 62.86%, compared with the control group were 34.29%, 31.34% have obvious difference（P〈0.05）. Observation group total effective rate was 97.14%, control group is 74.29%, 77.14% respectively, the two groups of same lower contrast group, the difference was statistically significant（P〈0.05）. The cough, asthma, lung＇s sound of observation group three symptom scores significantly lower than control group in both groups, the difference was statistically significant（P〈0.05）. In the incidence of adverse reactions, the observation group with a headache, weakness of muscle soreness, respiratory local discomfort, fever was 14.29%, and the two groups in the control group 14.29%, 17.14%,there was no statistically significant difference. Conclusion Atomization inhalation human recombinant interferon α1b treatment of infantile viral pneumonia clinical curative effect, adverse reaction is low, is worth further promotion and clinical application.